A067630 Stock Overview
Develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
HLB Life Science Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,260.00 |
| 52 Week High | ₩18,000.00 |
| 52 Week Low | ₩5,860.00 |
| Beta | -0.30 |
| 1 Month Change | -30.13% |
| 3 Month Change | -39.69% |
| 1 Year Change | -62.52% |
| 3 Year Change | -38.18% |
| 5 Year Change | -35.14% |
| Change since IPO | 263.23% |
Recent News & Updates
The Price Is Right For HLB Life Science Co., Ltd. (KOSDAQ:067630) Even After Diving 41%
Mar 31
We Think Shareholders Should Be Aware Of Some Factors Beyond HLB Life Science's (KOSDAQ:067630) Profit
Mar 27Recent updates
The Price Is Right For HLB Life Science Co., Ltd. (KOSDAQ:067630) Even After Diving 41%
Mar 31We Think Shareholders Should Be Aware Of Some Factors Beyond HLB Life Science's (KOSDAQ:067630) Profit
Mar 27Market Participants Recognise HLB Life Science Co., Ltd.'s (KOSDAQ:067630) Revenues
Feb 11Is HLB Life Science (KOSDAQ:067630) A Risky Investment?
Jan 03HLB Life Science Co., Ltd.'s (KOSDAQ:067630) Popularity With Investors Under Threat As Stock Sinks 26%
Oct 24What HLB Life Science Co., Ltd.'s (KOSDAQ:067630) P/S Is Not Telling You
Aug 30HLB Life Science (KOSDAQ:067630) Shareholders Should Be Cautious Despite Solid Earnings
May 21HLB Life Science Co., Ltd.'s (KOSDAQ:067630) 25% Share Price Surge Not Quite Adding Up
Mar 15HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?
Apr 12Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?
Feb 14Is HLB Life Science (KOSDAQ:067630) A Risky Investment?
Jan 10We're Not So Sure You Should Rely on HLB Life Science's (KOSDAQ:067630) Statutory Earnings
Dec 06Shareholder Returns
| A067630 | KR Healthcare | KR Market | |
|---|---|---|---|
| 7D | -2.8% | 5.3% | 6.0% |
| 1Y | -62.5% | -35.4% | -10.0% |
Return vs Industry: A067630 underperformed the KR Healthcare industry which returned -35.4% over the past year.
Return vs Market: A067630 underperformed the KR Market which returned -10% over the past year.
Price Volatility
| A067630 volatility | |
|---|---|
| A067630 Average Weekly Movement | 12.5% |
| Healthcare Industry Average Movement | 9.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in KR Market | 12.5% |
| 10% least volatile stocks in KR Market | 2.8% |
Stable Share Price: A067630's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A067630's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 145 | Sangwoo Nam | www.hlb-ls.com |
HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the company is involved in the waste heat recovery, cogeneration power generation, facility installation, solar energy, photovoltaic power generation, bioenergy, geothermal energy, waste energy, wind power, and fuel cell businesses, as well as manufactures and sells disposable syringes.
HLB Life Science Co., Ltd. Fundamentals Summary
| A067630 fundamental statistics | |
|---|---|
| Market cap | ₩762.60b |
| Earnings (TTM) | ₩6.14b |
| Revenue (TTM) | ₩102.24b |
124.2x
P/E Ratio7.5x
P/S RatioIs A067630 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A067630 income statement (TTM) | |
|---|---|
| Revenue | ₩102.24b |
| Cost of Revenue | ₩104.81b |
| Gross Profit | -₩2.57b |
| Other Expenses | -₩8.71b |
| Earnings | ₩6.14b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 50.38 |
| Gross Margin | -2.51% |
| Net Profit Margin | 6.00% |
| Debt/Equity Ratio | 30.8% |
How did A067630 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/15 19:35 |
| End of Day Share Price | 2025/04/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HLB Life Science Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.